SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma

The purpose of this study is to evaluate the safety, tolerability and preliminary antitumor activity of SKB500 combinations in patients with Esophageal Squamous Cell Carcinoma. The study is divided into two parts: the safety run-in phase and the cohort expansion phase.

Trial Details

NCT ID
NCT07700667
Phase
PHASE2
Sponsor
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Squamous Cell Esophageal Cancer
Interventions
  • SKB500
  • Tislelizumab
  • Cisplatin
  • 5 - FU
Locations (sample)
  • Changchun, China|43.88,125.32278
  • Chengdu, China|30.66667,104.06667
  • Chengdu, China|30.66667,104.06667
  • Chengdu, China|30.66667,104.06667
  • Chongqing, China|29.56026,106.55771

Key Eligibility Criteria

  • Age ≥18 years and ≤75 years
  • Histologically or cytologically confirmed unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC), who are…
  • Safety run-in phase (Cohort 1, 2 and 3): received no more than 1 prior line of systemic therapy for locally advanced or metastatic ESCC.
  • Safety run-in phase (Cohort 4) and cohort expansion phase: no prior systemic therapy for locally advanced or metastatic ESCC.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Squamous Cell Esophageal Cancer Trials on Trialify →